

# ZERO CANDIDA

---

**TSXV: ZCT**

---

**FSE: 9L2**

---

**OTCQB: ZCTFF**

---



# FORWARD-LOOKING STATEMENTS

This presentation contains forward-looking statements based on expectations, forecasts, and assumptions about future events or performance. These statements can be identified by terms such as “will,” “may,” “estimate,” “expect,” “plan,” “project,” “intend,” “anticipate,” or similar terms. These statements reflect the Company’s current expectations but involve inherent risks, uncertainties, and factors that may cause actual results to differ materially from what is expressed or implied.

Risks that could impact these statements include, but are not limited to, negative cash flow, limited product acceptance, clinical and operational risks, funding conditions, competition, reliance on key management, regulatory approval challenges, intellectual property issues, exchange rate fluctuations, and general economic conditions.

Forward-looking statements in this presentation also relate to anticipated growth, product development, and expected revenue and margins. Readers should not place undue reliance on these statements, as they are based on assumptions that may prove inaccurate. The Company does not undertake any obligation to update or revise these statements, except as required by law, and will only update them through formal filings or press releases. These forward-looking statements involve assumptions that may be incorrect. For example, the Company assumes market acceptance of its products and successful business expansion, but these assumptions may prove incorrect. Investors should conduct their own due diligence and understand the risks involved in investing in the Company.

Past performance or trends mentioned in this presentation are not indicative of future results. Even if future outcomes align with forward-looking statements, they may not be indicative of future performance. The price of the Company’s securities may fluctuate significantly due to factors such as market sentiment, capital market volatility, or changes in investor confidence.



# ZCT OVERVIEW

## Revolutionizing Women's Health

- Groundbreaking technological advancements in FemTech; industry expected to exceed \$115 Billion in the next 4 years.
- Founded by a team of experienced healthcare experts and entrepreneurs.
- Fully patented in Africa, with applications filed in Europe, USA, and Brazil.
- Funded for clinical trials and agreements secured with leading hospitals in Israel and Europe.
- Leveraging AI and controlled "Blue Light" in ZC-01 Device.
- Eliminates candida fungus without chemicals or side effects; showing a 99.999% success rate in preclinical tests.





# CANDIDIASIS



**AFFECTS 3 OUT OF 4 WOMEN WORLDWIDE IN THEIR LIFETIME**



**POORLY UNDERSTOOD AND INCREASINGLY DRUG RESISTANT**





**RECCURENT FOR HUNDREDS OF MILLIONS OF WOMEN EACH YEAR**



**HIGHEST PREVALENCE SEEN IN WOMEN BETWEEN 24 TO 34 YEARS OLD**

**Vulvo-Vaginal Candidiasis (“VVC”) is a fungal infection causing irritation, discharge, and intense itchiness of the vagina and vulva.**




\*based only on studies in US



# CURRENT TREATMENT

## Standard Therapy

- **Vaginal Ovules**
- **Creams**
- **Oral Drugs**



**In many cases  
are ineffective...**

## Therapeutic Failures

### Host Susceptibilities

**Alteration in the immune system**

- **Immunosuppressive therapy (organ transplant, cancer, AIDS)**
- **Chronic candidiasis**

### Microbial Resistance

**Reduction in the intracellular level of drug**

- **Biofilm presence**
- **Modern world overuse and low response to drugs**

### Lack of Drug Efficacy

**Low drug bio-availability**

- **Side effects of antifungal drugs**
- **Short time of drug efficiency and high recurrence**



# THE TECHNOLOGY

A **non-drug** blue light therapy in a **SMART** vaginal diagnostic device designed for the millions of women suffering from candidiasis.

Offering precise and personalized treatment, with individualized light frequency targeting, to produce **99.999% fungal eradication** in only **3 hours**.

Zero Candida is a novel diagnostic and therapeutic technology platform with a de novo regulatory pathway.



# ZC-01 DEVICE

- **Transparent Gel Matrix**
- **Image Sensor**
- **Temperature Sensor**
- **pH Sensor**
- **Discreet and Patient-Centric Design**
- **Novel Therapeutic Antimicrobial Blue Light**
- **Bleeding Sensor**
- **Wi-Fi Chip**



# UPCOMING MILESTONES

**Q1**

- **Frankfurt Stock Exchange Listing**
- **Finalize Human Prototype**

**Q2**

- **OTC Listing & DTC Eligibility**
- **Attend Gynaecology/Investor Conferences**

**Q3**

- **Finish pre-clinical animal study**
- **Commence clinical trials**


**Q4**

- **Present results to FDA for review**
- **Apply for 510(k)**



# ZERO CANDIDA

**TSXV: ZCT OTCQB: ZCTFF FSE: 9L2**



[zero-candida.com](https://www.zero-candida.com)



## Contact Details:



[info@zero-candida.com](mailto:info@zero-candida.com)



+1 (647) 874 3767

